Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
Active, not recruiting · Phase 2 · NCT04942210
Conditions: Yellow Fever, Healthy Volunteers
At a glance
- Research payments reported, 2025
- $301,147
- U.S. investigators named
- 12
- Sites paid
- 13
- Planned or actual enrollment
- 568
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- Yellow fever vaccine (produced on serum-free Vero cells) (biological), Yellow fever vaccine (biological)
- Dates
- Started 2021-07-01; completion 2027-06-29
- Results posted
- Yes
The primary objective of the study is to demonstrate the non-inferiority of the antibody response in terms of seroconversion rate 28 days after vaccine administration of one dose of yellow fever vaccine (vYF) compared to the antibody response after one dose of the YF-VAX control vaccine in yellow fever naïve participants. The secondary objectives of the study are: * To describe the immune response to yellow fever in both vaccine groups before and after vYF or YF-VAX administration. * To describe the safety profile of vYF vaccine in comparison to the safety profile of the control YF-VAX. * To describe the biosafety profile of vYF in comparison to the biosafety profile of the control YF-VAX.
From ClinicalTrials.gov, last updated 2026-09-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $301,147 in research payments for this study in 2025 (277 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Srilatha Edupuganti, MD Infectious Disease · Atlanta, GA
- Mark J. Mulligan, M.D. Infectious Disease · Atlanta, GA
- Chen S. Tan, M.D. Infectious Disease · Iowa City, IA
- Scott P. Striplin, M.D. OB-GYN (Obstetrics & Gynecology) · Covington, LA
- Ai-ris Y. Collier, M.D. Maternal-Fetal Medicine (High-Risk Pregnancy) · Boston, MA
- Kawsar R. Talaat, M.D. Infectious Disease · Baltimore, MD
- Sarah George, M.D. Infectious Disease · Saint Louis, MO
- Brandon J. Essink, M.D. Family Medicine · Creighton, NE
- Matthew G. Davis, MD Family Medicine · Rochester, NY
- Kristopher M. Paolino, M.D. Infectious Disease · Syracuse, NY
- David Fried, MD Internal Medicine · East Greenwich, RI
- James T. Peterson, MD OB-GYN (Obstetrics & Gynecology) · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Emory University Hospital, GA $43,691
- Meridian Clinical Research Llc $43,430
- New York University $43,068
- Velocity Clinical Research, Savannah $31,520
- Johns Hopkins University $29,380
- Rochester Clinical Research $27,338
- The Research Found of State University of New York $25,904
- Rochester Clinical Research Inc $18,225
- Beth Israel Deaconess Medical Center, MA $15,579
- Velocity Clinical Research,inc $10,551
- J Lewis Research,inc $7,767
- Saint Louis University Neurosurge $3,632
- St Louis University $1,061
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.